Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A

Table 1 Patient characteristics (as treated)

	TARGIT-A							EBRT+boost
	IORT (n = 25)		EBRT (n = 46)		IORT-EBRT (n = 16)			IORT-boost (n=90)		EBRT-boost (n=53)
	No.	%	No.	%	No.	%	P*	No.	%	No.	%	P**
Age, years
Mean	65.5		65.2		61.8		0.276	60.1		49.9		<0.001
SD	8.5		8.2		6.0			11.1		9.2
Married/partnered	14	58	22	48	13	81	0.066	58	64	39	76	0.191
Employed	4	16	9	20	0	0	0.185	27	31	31	60	<0.001
Months since BCS
Mean	32.7		30.6		35.6		0.641	34.2		47.5		<0.001
SD	19.1		17.2		19.6			13.7		7.4
Tumor size
0-1 cm	8	32	14	30	3	19	0.376	13	14	6	11	0.414
1-2 cm	16	64	25	34	9	56		49	54	23	43
> 2 cm	1	4	7	15	4	25		28	31	24	45
Nodal involvement
N0	23	92	36	78	14	88	0.622	66	73	34	65^a	0.253
N1	2	9	9	20	2	12		20	22	11	21
> N1	0	0	1	2	0	0		4	4	7	13
ALND	4	16	14	30	4	25	0.409	55	61	41	79^a	<0.001
Chemotherapy	4	17	5	11	2	12	0.908	18	20	36	68	<0.001
Endocrine therapy	23	96	40	93	13	81	0.322	70	78	36	86	0.349
Radiotherapy of supra- and infraclavicular nodes	0	0	2	4	0	0	0.693	7	8	10	19	0.049
Medical comorbidities ≥2^b	14	56	37	80	11	69	0.091	49	54	9	17	<0.001

Abbreviations: TARGIT-A, TARG eted I ntra-operative radioT herapy versus whole breast radiotherapy for breast cancer, IORT, intraoperative radiotherapy, EBRT, external beam whole breast radiotherapy, ALND, axillary lymph node dissection.
* IORT versus EBRT versus IORT-EBRT.
** IORT-EBRT versus IORT-boost versus EBRT-boost.
^a One patient without axillary assessment.
^b Coexisting medical conditions were assessed by medical record review and by patient self-report. A medical comorbidity was defined as having two or more physical illnesses or injuries that needed long-term treatment.

ISSN: 1748-717X